Vaxcyte, Inc. (PCVX) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The Phase 3 study “A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination” aims to test how well VAX-31 works and how safe it is in adults 50 and older. It matters because strong data here could support broader use of Vaxcyte, Inc.’s next-generation pneumococcal vaccine and shape its future revenue outlook.
The trial compares a single intramuscular dose of VAX-31, a 31-valent pneumococcal conjugate vaccine, against PCV20 (Prevnar 20), the current leading 20-valent shot. The goal is to see if VAX-31 can offer broader protection than today’s standard vaccines in people who have already received other pneumococcal shots.
This is an interventional Phase 3 study with participants randomly assigned to either VAX-31 or PCV20 in parallel groups. The trial is double-blind with masking of participants, care providers, investigators, and outcome assessors, and its main purpose is prevention, meaning it looks at how well the vaccines help stop pneumococcal disease rather than treat existing illness.
The study was first submitted on February 11, 2026, signaling the formal start of this late-stage effort and a clear move toward registrational data. The most recent update was filed on February 18, 2026, which shows the protocol is current and that progress, such as site activation and recruiting status, is being actively maintained.
For investors, this Phase 3 update is a key milestone for Vaxcyte (PCVX) as it moves into direct head-to-head testing against Pfizer’s Prevnar 20, the entrenched market leader. Strong safety and immune response data could support a premium profile for VAX-31, driving higher long-term sales expectations and improving sentiment toward PCVX, while also signaling rising competitive pressure for incumbents in the adult pneumococcal vaccine market.
The VAX-31 Phase 3 trial in previously vaccinated adults is active and recruiting, with ongoing updates and further details available on the ClinicalTrials.gov portal under identifier NCT07425392.
To learn more about PCVX’s potential, visit the Vaxcyte, Inc. drug pipeline page.